Exscientia
Exscientia, a pioneering force in the field of artificial intelligence-driven drug discovery, is headquartered in the United Kingdom. Founded in 2012, the company has rapidly established itself as a leader in the biotechnology industry, focusing on the integration of AI with traditional pharmaceutical development processes. With a strong operational presence in Europe and North America, Exscientia is renowned for its unique approach to designing and optimising drug candidates, significantly reducing the time and cost associated with bringing new therapies to market. The company’s core services include AI-based drug design and precision medicine, which leverage advanced algorithms to enhance the efficiency of drug discovery. Exscientia's notable achievements include collaborations with major pharmaceutical companies and a robust pipeline of drug candidates, positioning it as a key player in the evolving landscape of drug development.
DitchCarbon Score
How does Exscientia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Exscientia's score of 10 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Exscientia's reported carbon emissions
In 2023, Exscientia reported total carbon emissions of approximately 357,220 kg CO2e in Great Britain, with Scope 1 emissions at about 53,420 kg CO2e and Scope 2 emissions (market-based) at around 88,240 kg CO2e. This marks a significant increase from their 2022 emissions, which were not disclosed for the GB region but were approximately 92,060 kg CO2e globally. In 2021, Exscientia's emissions in Great Britain were about 83,840 kg CO2e, with Scope 1 emissions at approximately 9,490 kg CO2e and Scope 2 emissions (market-based) at around 69,730 kg CO2e. The company has shown fluctuations in emissions over the years, with a notable increase in 2023. Despite these figures, Exscientia has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company continues to operate within the context of the pharmaceutical and biotechnology industry, which is increasingly focused on sustainability and reducing carbon footprints.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 5,940 | 0,000 | 00,000 |
| Scope 2 | 66,790 | 00,000 | 0,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Exscientia is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
